Reprogramming of myeloid cells of the tumor microenvironment – a new approach in the immunotherapy of malignant neoplasms

Abstract

Modern therapy of a cancer patient, especially immunotherapy, must take into account and overcome the immunosuppression created inside the tumor and, in general, in the body affected by a malignant neoplasm. Without overcoming immunosuppression, it is impossible to achieve effective elimination of malignant cells by the forces of immune mechanisms.

The immunosuppressive properties of the tumor microenvironment are formed by both malignant and non-malignant cells and the substances they produce. Myeloid cells, tumor-associated macrophages, intratumoral dendritic cells, and myeloid suppressors attracted by the tumor, play a significant role in creating an immunosuppressive milieu inside the tumor. These cells produce soluble inhibitors of immune responses such as IDO, TGF-β, IL-10, prostaglandins, and also exhibit on their surface molecules that have the ability to suppress immune cells, in particular, PD-L1/2 molecules that cause functional paralysis of T cells or even their death.

In this literature review, we consider the immunosuppressive properties of macrophages, dendritic cells, and other tumor-associated myeloid cells aiming to overcome this mechanism of immunosuppression during the treatment of cancer patients. We present an analysis of the literature and our own results of the correction of immunity by targeting of tumor myeloid cells. The presented data suggest that a correction of the tumor myeloid cells’ properties is new effective approach in the immunotherapy of malignant neoplasms.

Keywords:malignant neoplasm; microenvironment; immunosuppression; myeloid cells; reprogramming; immunotherapy

For citation: Ataullakhanov R.I., Ushakova E.I., Al Khudhur S.А., Pichugin A.V., Lebedeva E.S. Reprogramming of myeloid cells of the tumor microenvironment – a new approach in the immunotherapy of malignant neoplasms. Immunologiya. 2022; 43 (4): 375–88. DOI: https://doi.org/10.33029/0206-4952-2022-43-4-375-388 (in Russian)

Funding. The study was supported by a grant from the Russian Science Foundation (project No. 20-15-00391).

Conflict of interests. The authors declare no conflict of interests.

Authors’ contribution. Concept, literature analysis, article writing – Ataullakhanov R.I.; literature analysis, article writing and editing – Ushakova E.I.; literature analysis, article writing – Al Khudur S.A.; literature analysis, article editing – Pichugin A.V.; literature analysis, article editing – Lebedeva E.S.

References

1.Zhang Y., Cheng S., Zhang M., Zhen L., Pang D., Zhang Q., Li Z. High-infiltration of tumor-associated macrophages predicts unfavorable clinical outcome for node-negative breast cancer. PLoS One. 2013; 8: e76147. DOI: https://doi.org/10.1371/journal.pone.0076147

2.Xue Y., Tong L., Liu F.L., Liu A., Zeng S., Xiong Q., Yang Z., He X., Sun Y., Xu C. Tumor‑infiltrating M2 macrophages driven by specific genomic alterations are associated with prognosis in bladder cancer. Oncol. Rep. 2019; 42: 581–94. DOI: https://doi.org/10.3892/or.2019.7196

3.Kumar A.T., Knops A., Swendseid B., Martinez-Outschoom U., Harshyne L., Philp N., Rodeck U., Luginbuhl A., Cognetti D., Johnson J., Curry J. Prognostic significance of tumor-associated macrophage content in head and neck squamous cell carcinoma: a meta-analysis. Front. Oncol. 2019; 9: 656. DOI: https://doi.org/10.3389/fonc.2019.00656

4.Nishie A., Ono M., Shono T., Fukushi J., Otsubo M., Onoue H., Ito Y., Inamura T., Ikezaki K., Fukui M., Iwaki T., Kuwano M. Macrophage infiltration and heme oxygenase-1 expression correlate with angiogenesis in human gliomas. Clin. Cancer Res. 1999; 5: 1107–13.

5.Torisu H., Ono M., Kiryu H., Furue M., Ohmoto Y., Nakayama J., Nishioka Y., Sone S., Kuwano M. Macrophage infiltration correlates with tumor stage and angiogenesis in human malignant melanoma: Possible involvement of TNFα and IL-1α Int. J. Cancer. 2000; 85: 182–8. DOI: https://doi.org/10.1002/(SICI)1097-0215(20000115)85:2<182::AID-IJC6>3.0.CO;2-M

6.Cao J., Liu J., Xuan Z., Zhu X., Zhao X., Qian B.-Z. Prognostic role of tumour-associated macrophages and macrophage scavenger receptor 1 in prostate cancer: a systematic review and meta-analysis. Oncotarget. 2017; 8: 83 261–9. DOI: https://doi.org/10.18632/oncotarget.18743

7.Nishida N., Yano H., Nishida T., Kamura T., Kojiro M. Angiogenesis in cancer. Vasc. Health Risk Manag. 2006; 2: 213–9. DOI: https://doi.org/10.2147/vhrm.2006.2.3.213

8.Ribatti D., Nico B., Crivellato E., Vacca A. Macrophages and tumor angiogenesis. Leukemia. 2007; 21: 2085–9. DOI: https://doi.org/10.1038/sj.leu.2404900

9.Riabov V., Gudima A., Wang N., Mickley A., Orekhov A., Kzhyshkowska J. Role of tumor associated macrophages in tumor angiogenesis and lymphangiogenesis. Front. Physiol. 2014; 5: 75. DOI: https://doi.org/10.3389/fphys.2014.00075

10.Quintero-Fabián S., Arreola R., Becerril-Villanueva E., Torres-Romero J.C., Arana-Argáez V., Lara-Riegos J., Ramírez-Camacho M.A., Alvarez-Sánchez M.E. Role of matrix metalloproteinases in angiogenesis and cancer. Front. Oncol. 2019; 9: 1370. DOI: https://doi.org/10.3389/fonc.2019.01370

11.Landskron G., De La Fuente M., Thuwajit P., Thuwajit C., Hermoso M.A. Chronic inflammation and cytokines in the tumor microenvironment. J. Immunol. Res. 2014; 2014: 1–19. DOI: https://doi.org/10.1155/2014/149185

12.Thomas S.J., Snowden J.A., Zeidler M.P., Danson S. The role of JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours. Br. J. Cancer. 2015; 113: 365–71. DOI: https://doi.org/10.1038/bjc.2015.233

13.Baker K.J., Houston A., Brint E. IL-1 Family members in cancer; two sides to every story. Front. Immunol. 2019; 10: 1197. DOI: https://doi.org/10.3389/fimmu.2019.01197

14.Xia L., Tan S., Zhou Y., Lin J., Wang H., Oyang L., Tian Y., Liu L., Su M., Wang H., Cao D., Liao Q. Role of the NFκB-signaling pathway in cancer. Onco Targets. Ther. 2018; 11: 2063–73. DOI: https://doi.org/10.2147/OTT.S161109

15.Wang J., Li D., Cang H., Guo B. Crosstalk between cancer and immune cells: Role of tumor-associated macrophages in the tumor microenvironment. Cancer Med. 2019; 8: 4709–21. DOI: https://doi.org/10.1002/cam4.2327

16.Oh S.A., Li M.O. TGF-β: guardian of T cell function. J. Immunol. 2013; 191: 3973–9. DOI: https://doi.org/10.4049/jimmunol.1301843

17.Landskron G., De La Fuente M., Thuwajit P., Thuwajit C., Hermoso M.A. Chronic inflammation and cytokines in the tumor microenvironment. J. Immunol. Res. 2014; 2014: 1–19. DOI: https://doi.org/10.1155/2014/149185

18.Corthay A. How do regulatory T cells work? Scand. J. Immunol. 2009; 70: 326–36. DOI: https://doi.org/10.1111/j.1365-3083.2009.02308.x

19.Palazon A., Goldrath A.W., Nizet V., Johnson R.S. HIF transcription factors, inflammation, and immunity. Immunity. 2015; 41: 518–28. DOI: https://doi.org/10.1016/j.immuni.2014.09.008

20.Shimizu K., Iyoda T., Okada M., Yamasaki S., Fujii S.-I. Immune suppression and reversal of the suppressive tumor microenvironment. Int. Immunol. 2018; 30: 445–55. DOI: https://doi.org/10.1093/intimm/dxy042

21.Ceci C., Atzori M.G., Lacal P.M., Graziani G. Targeting tumor-associated macrophages to increase the efficacy of immune checkpoint inhibitors: a glimpse into novel therapeutic approaches for metastatic melanoma. Cancers (Basel). 2020; 12 (11): 3401. DOI: https://doi.org/10.3390/cancers12113401

22.Noy R., Pollard J.W. Tumor-associated macrophages: from mechanisms to therapy. Immunity. 2014; 41: 49–61. DOI: https://doi.org/10.1016/j.immuni.2014.06.010

23.Liguori M., Buracchi C., Pasqualini F., Bergomas F., Pesce S., Sironi M., Grizzi F., Mantovani A., Belgiovine C., Allavena P. Functional TRAIL receptors in monocytes and tumor-associated macrophages: a possible targeting pathway in the tumor microenvironment. Oncotarget. 2016; 7: 41 662–76. DOI: https://doi.org/10.18632/oncotarget.9340

24.Intlekofer A.M., Thompson C.B. At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy. J. Leukoc. Biol. 2013; 94: 25–39. DOI: https://doi.org/10.1189/jlb.1212621

25.Vandenborre K., Van Gool S.W., Kasran A., Ceuppens J.L., Boogaerts M.A., Vandenberghe P. Interaction of CTLA-4 (CD152) with CD80 or CD86 inhibits human T-cell activation. Immunology. 1999; 98: 413–21. DOI: https://doi.org/10.1046/j.1365-2567.1999.00888.x

26.Popovic P.J., Zeh I.H.J., Ochoa J.B. Arginine and Immunity. J. Nutr. 2007; 137: 1681S–6S. DOI: https://doi.org/10.1093/jn/137.6.1681S

27.Czystowska-Kuzmicz M., Sosnowska A., Nowis D., Ramji K., Szajnik M., Chlebowska-Tuz J., Wolinska E., Gaj P., Grazul M., Pilch Z., et al. Small extracellular vesicles containing arginase-1 suppress T-cell responses and promote tumor growth in ovarian carcinoma. Nat. Commun. 2019; 10: 1–16. DOI: https://doi.org/10.1038/s41467-019-10979-3

28.Rodriguez P.C., Quiceno D.G., Ochoa A.C. l-arginine availability regulates T-lymphocyte cell-cycle progression. Blood. 2006; 109: 1568–73. DOI: https://doi.org/10.1182/blood-2006-06-031856

29.Priceman S.J., Sung J.L., Shaposhnik Z., Burton J.B., Torres-Collado A.X., Moughon D.L., Johnson M., Lusis A.J., Cohen D.A., Iruela-Arispe M.L., Wu L. Targeting distinct tumor-infiltrating myeloid cells by inhibiting CSF-1 receptor: combating tumor evasion of antiangiogenic therapy. Blood. 2010; 115 (7): 1461–71. DOI: https://doi.org/10.1182/blood-2009-08-237412

30.Mok S., Koya R.C., Tsui C., Xu J., Robert L., Wu L., Graeber T., West B.L., Bollag G., Ribas A. Inhibition of CSF-1 receptor improves the antitumor efficacy of adoptive cell transfer immunotherapy. Cancer Res. 2014; 74 (1): 153–61. DOI: https://doi.org/10.1158/0008-5472.CAN-13-1816

31.Dai X.M., Ryan G.R., Hapel A.J., Dominguez M.G., Russell R.G., Kapp S., Sylvestre V., Stanley E.R. Targeted disruption of the mouse colony-stimulating factor 1 receptor gene results in osteopetrosis, mononuclear phagocyte deficiency, increased primitive progenitor cell frequencies, and reproductive defects. Blood. 2002; 99 (1): 111–20. DOI: https://doi.org/10.1182/blood.v99.1.111

32.Li J., Chen K., Zhu L., Pollard J.W. Conditional deletion of the colony stimulating factor-1 receptor (c-fms proto-oncogene) in mice. Genesis. 2006; 44 (7): 328–35. DOI: https://doi.org/10.1002/dvg.20219

33.Kerkar S.P., Restifo N.P. Cellular constituents of immune escape within the tumor microenvironment. Cancer Res. 2012; 72 (13): 3125–30. DOI: https://doi.org/10.1158/0008-5472.CAN-11-4094

34.Gabrilovich D.I., Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 2009; 9 (3): 162–74. DOI: https://doi.org/10.1038/nri2506

35.Fujiwara T., Yakoub M.A., Chandler A., Christ A.B., Yang G., Ouerfelli O., Rajasekhar V.K., Yoshida A., Kondo H., Hata T., Tazawa H., Dogan Y., Moore M.A.S., Fujiwara T., Ozaki T., Purdue E., Healey J.H. CSF1/CSF1R signaling inhibitor pexidartinib (PLX3397) reprograms tumor-associated macrophages and stimulates T-cell infiltration in the sarcoma microenvironment. Mol. Cancer Ther. 2021; 20 (8): 1388–99. DOI: https://doi.org/10.1158/1535-7163.MCT-20-0591

36.Wesolowski R., Sharma N., Reebel L., Rodal M.B., Peck A., West B.L., Marimuthu A., Severson P., Karlin D.A., Dowlati A., Le M.H., Coussens L.M., Rugo H.S. Phase Ib study of the combination of pexidartinib (PLX3397), a CSF-1R inhibitor, and paclitaxel in patients with advanced solid tumors. Ther. Adv. Med. Oncol. 2019; 11: 1758835919854238. DOI: https://doi.org/10.1177/1758835919854238

37.Smith C.C., Levis M.J., Frankfurt O., Pagel J.M., Roboz G.J., Stone R.M., Wang E.S., Severson P.L., West B.L., Le M.H., Kayser S., Lam B., Hsu H.H., Zhang C., Bollag G., Perl A.E. A phase 1/2 study of the oral FLT3 inhibitor pexidartinib in relapsed/refractory FLT3-ITD-mutant acute myeloid leukemia. Blood Adv. 2020; 4 (8): 1711–21. DOI: https://doi.org/10.1182/bloodadvances.2020001449

38.Lamb Y.N. Pexidartinib: first approval. Drugs. 2019; 79 (16): 1805–12. DOI: https://doi.org/10.1007/s40265-019-01210-0

39.Cassier P.A., Italiano A., Gomez-Roca C.A., Le Tourneau C., Toulmonde M., Cannarile M.A., Ries C., Brillouet A., Müller C., Jegg A.M., Bröske A.M., Dembowski M., Bray-French K., Freilinger C., Meneses-Lorente G., Baehner M., Harding R., Ratnayake J., Abiraj K., Gass N., Noh K., Christen R.D., Ukarma L., Bompas E., Delord J.P., Blay J.Y., Rüttinger D. CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study. Lancet Oncol. 2015; 16 (8): 949–56. DOI: https://doi.org/10.1016/S1470-2045(15)00132-1

40.Gomez-Roca C., Cassier P., Zamarin D., Machiels J.P., Luis Perez Gracia J., Stephen Hodi F., Taus A., Martinez Garcia M., Boni V., Eder J.P., Hafez N., Sullivan R., Mcdermott D., Champiat S., Aspeslagh S., Terret C., Jegg A.M., Jacob W., Cannarile M.A., Ries C., Korski K., Michielin F., Christen R., Babitzki G., Watson C., Meneses-Lorente G., Weisser M., Rüttinger D., Delord J.P., Marabelle A. Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade. J. Immunother. Cancer. 2022; 10 (5): e004076. DOI: https://doi.org/10.1136/jitc-2021-004076

41.Falchook G.S., Peeters M., Rottey S., Dirix L.Y., Obermannova R., Cohen J.E., Perets R., Frommer R.S., Bauer T.M., Wang J.S., Carvajal R.D., Sabari J., Chapman S., Zhang W., Calderon B., Peterson D.A. A phase 1a/1b trial of CSF-1R inhibitor LY3022855 in combination with durvalumab or tremelimumab in patients with advanced solid tumors. Invest. New Drugs. 2021; 39 (5): 1284–97. DOI: https://doi.org/10.1007/s10637-021-01088-4

42.Jaiswal S., Jamieson C.H., Pang W.W., Park C.Y., Chao M.P., Majeti R., Traver D., van Rooijen N., Weissman I.L. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell. 2009; 138 (2): 271–85. DOI: https://doi.org/10.1016/j.cell.2009.05.046

43.Eladl E., Tremblay-LeMay R., Rastgoo N., Musani R., Chen W., Liu A., Chang H. Role of CD47 in hematological malignancies. J. Hematol. Oncol. 2020; 13 (1): 96. DOI: https://doi.org/10.1186/s13045-020-00930-1

44.Dheilly E., Majocchi S., Moine V., Didelot G., Broyer L., Calloud S., Malinge P., Chatel L., Ferlin W.G., Kosco-Vilbois M.H., Fischer N., Masternak K. Tumor-directed blockade of CD47 with bispecific antibodies induces adaptive antitumor immunity. Antibodies (Basel). 2018; 7 (1): 3. DOI: https://doi.org/10.3390/antib7010003

45.Yanagita T., Murata Y., Tanaka D., Motegi S.I., Arai E., Daniwijaya E.W., Hazama D., Washio K., Saito Y., Kotani T., Ohnishi H., Oldenborg P.A., Garcia N.V., Miyasaka M., Ishikawa O., Kanai Y., Komori T., Matozaki T. Anti-SIRPα antibodies as a potential new tool for cancer immunotherapy. JCI Insight. 2017; 2 (1): e89140. DOI: https://doi.org/10.1172/jci.insight.89140

46.Sikic B.I., Lakhani N., Patnaik A., Shah S.A., Chandana S.R., Rasco D., Colevas A.D., O’Rourke T., Narayanan S., Papadopoulos K., Fisher G.A., Villalobos V., Prohaska S.S., Howard M., Beeram M., Chao M.P., Agoram B., Chen J.Y., Huang J., Axt M., Liu J., Volkmer J.P., Majeti R., Weissman I.L., Takimoto C.H., Supan D., Wakelee H.A., Aoki R., Pegram M.D., Padda S.K. First-in-human, first-in-class phase I trial of the anti-CD47 antibody Hu5F9-G4 in patients with advanced cancers. J. Clin. Oncol. 2019; 37 (12): 946–53. DOI: https://doi.org/10.1200/JCO.18.02018

47.Jalil A.R., Andrechak J.C., Discher D.E. Macrophage checkpoint blockade: results from initial clinical trials, binding analyses, and CD47-SIRPα structure-function. Antib. Ther. 2020; 3 (2): 80–94. DOI: https://doi.org/10.1093/abt/tbaa006

48.Weiskopf K., Ring A.M., Ho C.C., Volkmer J.P., Levin A.M., Volkmer A.K., Ozkan E., Fernhoff N.B., van de Rijn M., Weissman I.L., Garcia K.C. Engineered SIRPα variants as immunotherapeutic adjuvants to anticancer antibodies. Science. 2013; 341 (6141): 88–91. DOI: https://doi.org/10.1126/science.1238856

49.Müller E., Christopoulos P.F., Halder S., Lunde A., Beraki K., Speth M., Oynebraten I., Corthay A. Toll-like receptor ligands and interferon-γ synergize for induction of antitumor M1 macrophages. Front. Immunol. 2017; 8: 1383. DOI: https://doi.org/10.3389/fimmu.2017.01383

50.Pan Y., Yu Y., Wang X., Zhang T. Tumor-associated macrophages in tumor immunity. Front. Immunol. 2020; 11: 583084. DOI: https://doi.org/10.3389/fimmu.2020.583084

51.Liu S.X., Gustafson H.H., Jackson D.L., Pun S.H., Trapnell C. Trajectory analysis quantifies transcriptional plasticity during macrophage polarization. Sci. Rep. 2020; 10 (1): 12273. DOI: https://doi.org/10.1038/s41598-020-68766-w

52.Hörhold F., Eisel D., Oswald M., Kolte A., Röll D., Osen W., Eichmüller S.B., König R. Reprogramming of macrophages employing gene regulatory and metabolic network models. PLoS Comput. Biol. 2020; 16 (2): e1007657. DOI: https://doi.org/10.1371/journal.pcbi.1007657

53.Ravichandran S., Bhatt B., Balaji K.N., Chandra N. Combinatorial transcriptional codes specify macrophage polarization destinations. BioRxiv. 2021.10.19.464946; DOI: https://doi.org/10.1101/2021.10.19.464946

54.Tan Y., Wang M., Zhang Y., Ge S., Zhong F., Xia G., Sun C. Tumor-associated macrophages: a potential target for cancer therapy. Front. Oncol. 2021; 11: 693517. DOI: https://doi.org/10.3389/fonc.2021.693517

55.Zhou J., Tang Z., Gao S., Li C., Feng Y., Zhou X. Tumor-associated macrophages: recent insights and therapies. Front. Oncol. 2020; 10: 188. DOI: https://doi.org/10.3389/fonc.2020.00188

56.Bagaev A.V., Rybinets A.S., Fedorova A.A., Ushakova E.I., Lebedeva E.S., Pichugin A.V., Ataullakhanov R.I. Synergism of TLR3 and TLR4 agonists during reprogramming of macrophages to antitumor state. Immunologiya. 2021; 42 (6): 615–30. DOI: https://doi.org/10.33029/0206-4952-2021-42-6-615-630 (in Russian)

57.Lebedeva E.S., Bagaev A.V., Garaeva A.Y., Chulkina M.M., Pichugin A.V., Ataullakhanov R.I. The cooperative interaction of TLR4-, TLR9- and NOD2-signaling pathways in mouse macrophages. Immunologiya. 2018; 39 (1): 4–11. DOI: http://dx.doi.org/10.18821/0206-4952-2018-39-1-4-11 (in Russian)

58.Pichugin A.V., Bagaev A.V., Lebedeva E.S., Chulkina M.M., Ataullakhanov R.I. Combined activation with agonists of TLR4, TLR9 AND NOD2 receptors synergistically increases production of cytokine-proteins in mouse macrophages. Immunologiya. 2018; 39 (4): 172–7. DOI: http://dx.doi.org/10.18821/0206-4952-2018-39-4-172-177 (in Russian)

59.Chulkina M.M., Bagaev A.V., Lebedeva E.S., Garaeva A.Ya., Pichugin A.V., Ataullakhanov R.I. Synergistic activation of inos, ifn-β, il12p40, il6, tnf-α genes transcription in macrophages under simultaneous influence with agonists of TLR4, TLR9 and NOD2 receptors. Immunologiya. 2018; 39 (4): 178–85. DOI: http://dx.doi.org/10.18821/0206-4952-2018-39-4-178-18 (in Russian)

60.Lebedeva E.S., Dzharullaeva A.Sh., Bagaev A.V., Erokhova A.S., Chulkina M.M., Tukhvatulin A.I., Pichugin A.V., Logunov D.Yu., Ataullakhanov R.I. Combined stimulation of receptors of TLR4, TLR9 and NOD2 synergistically increases protection of laboratory mice in lethal Salmonella enterica infection model. Immunologiya. 2018; 39 (5–6): 252–7. DOI: http://dx.doi.org/10.18821/0206-4952-2018-39-5-6-252-257 (in Russian)

61.Bagaev A.V., Garaeva A.Y., Lebedeva E.S., Pichugin A.V., Ataullakhanov R.I., Ataullakhanov F.I. Elevated pre-activation basal level of nuclear NF-κB in native macrophages accelerates LPS-induced translocation of cytosolic NF-κB into the cell nucleus. Sci. Rep. 2019; 9 (1): 4563. DOI: https://doi.org/10.1038/s41598-018-36052-5

62.Bagaev A., Pichugin A., Nelson E.L., Agadjanyan M.G., Ghochikyan A., Ataullakhanov R.I. Anticancer mechanisms in two murine bone marrow-derived dendritic cell subsets activated with TLR4 agonists. J. Immunol. 2018; 200 (8): 2656–69. DOI: https://doi.org/10.4049/jimmunol.1701126

63.Lebedeva E., Bagaev A., Pichugin A., Chulkina M., Lysenko A., Tutykhina I., Shmarov M., Logunov D., Naroditsky B., Ataullakhanov R. The differences in immunoadjuvant mechanisms of TLR3 and TLR4 agonists on the level of antigen-presenting cells during immunization with recombinant adenovirus vector. BMC Immunol. 2018; 19 (1): 26. DOI: https://doi.org/10.1186/s12865-018-0264-x

64.Ghochikyan A., Pichugin A., Bagaev A., Davtyan A., Hovakimyan A., Tukhvatulin A., Davtyan H., Shcheblyakov D., Logunov D., Chulkina M., Savilova A., Trofimov D., Nelson E.L., Agadjanyan M.G., Ataullakhanov R.I. Targeting TLR-4 with a novel pharmaceutical grade plant derived agonist, Immunomax®, as a therapeutic strategy for metastatic breast cancer. J. Transl. Med. 2014; 12: 322. DOI: https://doi.org/10.1186/s12967-014-0322-y

65.Ushakova E.I., Lebedeva E.S., Bagaev A.V., Pichugin A.V., Ataullakhanov R.I. Combined immunotherapy of metastatic carcinoma by resection of the primary tumor and subsequent reprogramming of macrophages and dendritic cells using a TLR4 agonist in laboratory mice. Immunologiya. 2021; 42 (5): 490–501. DOI: https://doi.org/10.33029/0206-4952-2021-42-5-490-501 (in Russian)

66.Ushakova E., Lebedeva E., Pichugin A., Ataullakhanov R. P08.04 Successful immunotherapy of the breast cancer metastatic disease in mice using a pharmaceutical TLR4-agonist induces systemic anti-tumor T cell response and long-term T cell memory. In: Journal for Immunotherapy of Cancer. 2021; 9. DOI: https://doi.org/10.1136/jitc-2021-ITOC8.48

67.Ushakova E., Savchenko M., Lebedeva E., Pichugin A., Ataullakhanov R. In situ anti-tumor immunization using the tumor microenvironment reprograming with a TLR4-agonist induces strong CD4 and CD8 T cells responses, long-living T cell memory, and protection against 4T1 metastatic breast cancer in mice. Conference: 6th European Congress of Immunology. Abstracts. Location Virtual. Date September 1–4, 2021. Eur. J. Immunol. 2021; 51 (S1): 391. Meeting Abstract number P-0822. DOI: https://doi.org/10.1002/eji.202170200

68.Kashfi K., Kannikal J., Nath N. Macrophage reprogramming and cancer therapeutics: role of iNOS-derived NO. Cells. 2021; 10 (11): 3194. DOI: https://doi.org/10.3390/cells10113194

69.Cai H., Zhang Y., Wang J., Gu J. Defects in Macrophage Reprogramming in Cancer Therapy: The Negative Impact of PD-L1/PD-1. Front. Immunol. 2021; 12: 690869. DOI: https://doi.org/10.3389/fimmu.2021.690869

70.Pan Y., Yu Y., Wang X., Zhang T. Tumor-associated macrophages in tumor immunity. Front. Immunol. 2020; 11: 583084. DOI: https://doi.org/10.3389/fimmu.2020.583084

71.Sarode P., Zheng X., Giotopoulou G.A., Weigert A., Kuenne C., Günther S., Friedrich A., Gattenlöhner S., Stiewe T., Brüne B., Grimminger F., Stathopoulos G.T., Pullamsetti S.S., Seeger W., Savai R. Reprogramming of tumor-associated macrophages by targeting β-catenin/FOSL2/ARID5A signaling: a potential treatment of lung cancer. Sci. Adv. 2020; 6 (23): eaaz6105. DOI: https://doi.org/10.1126/sciadv.aaz6105

72.Zhang F., Parayath N.N., Ene C.I., Stephan S.B., Koehne A.L., Coon M.E., Holland E.C., Stephan M.T. Genetic programming of macrophages to perform anti-tumor functions using targeted mRNA nanocarriers. Nat. Commun. 2019; 10 (1): 3974. DOI: https://doi.org/10.1038/s41467-019-11911-5

73.Sun L., Kees T., Almeida A.S., Liu B., He X.Y., Ng D., Han X., Spector D.L., McNeish I.A., Gimotty P., Adams S., Egeblad M. Activating a collaborative innate-adaptive immune response to control metastasis. Cancer Cell. 2021; 39 (10): 1361–1374.e9. DOI: https://doi.org/10.1016/j.ccell.2021.08.005

EDITOR-IN-CHIEF
EDITOR-IN-CHIEF
Musa R. Khaitov

Corresponding member of Russian Academy of Sciences, MD, Professor, Director of the NRC Institute of Immunology FMBA of Russia

Вскрытие
Medicine today

Уважаемые коллеги, до XI-го Национального конгресса с международным участием имени Н.О. Миланова "Пластическая хирургия, эстетическая медицина и косметология" осталось 3 дня! С 29 ноября по 1 декабря 2022 года в Москве пройдет XI Национальный конгресс "Пластическая хирургия,...

6-7 декабря 2022 года состоится юбилейная X конференция с международным участием "Креативная кардиология и кардиохирургия. Новые технологии диагностики и лечения заболеваний сердца", которая будет проходить в очном и онлайн-формате в ФГБУ "НМИЦ ССХ им. А.Н. Бакулева"...

Приглашаем 1 и 2 декабря в Москву на яркий профессиональный праздник - итоговую всероссийскую Школу РОАГ! Школа в Москве занимает особое место в образовательном цикле Школ РОАГ. На ней подводятся итоги прошедшего сезона, обсуждаются темы, которые вызывают наибольший интерес...


JOURNALS of «GEOTAR-Media»